Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback